Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body's ability to reject a transplanted organ.
The approval further adds to Biocon's portfolio of complex drug products and will be commercialised in the region expeditiously, it added.
Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.
The company reported a consolidated net loss of Rs 16 crore in Q2 FY25 as against a net profit of Rs 126 crore in Q2 FY24. Revenue from operations rose by 4% YoY to Rs 3,590 crore during the quarter.
Shares of Biocon shed 0.68% to Rs 370.40 on the BSE.